
Five-Year Study on Aveed’s Impact on PSA Levels in American Males with Hypogonadism
Reading Time: 2 minutes Introduction Prostate health remains a critical concern for American males, with prostate-specific antigen (PSA) levels serving as a key indicator for monitoring prostate conditions. Aveed, a testosterone undecanoate injection developed by Endo Pharmaceuticals, has been utilized for testosterone replacement therapy in men with hypogonadism. This study aims to explore the longitudinal effects of Aveed on PSA levels over a five-year period, providing valuable insights into its impact on prostate health among American males. Study Design and Methodology This longitudinal study involved 500 American males aged between 40 and 70 years, all diagnosed with hypogonadism and prescribed Aveed for testosterone replacement...